OMNIACTION
12.1.2022 16:30:07 CET | Business Wire | Press release
OmniAction is a new global organisation dedicated to measuring the social, health and sustainability impacts of the food system. It will create a science-based, verified and independent framework which will be made available as a public good to everyone working – and consuming – across food and agriculture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005650/en/
The official launch event will be held via a Zoom video conference at 4pm GMT on January 27th 2022. Those wishing to attend should sign up via this Eventbrite link .
Co-founder Tim Lang , Emeritus Professor at City University, London, says, “Poor nutrition should not be a trade-off for causing less damage to the environment; just as poor labour rights, land tenure, or food safety should not have to be traded off – we need to examine all these impacts.
“I first proposed a multi-criteria approach to food standards more than a decade ago, and now the technology makes it possible.
"It’s time to create a global, harmonised framework for food metrics which can act as a resource for the entire food system."
OmniAction co-founder Anya Doherty, CEO of Foodsteps , says, “We need a North Star in sustainability benchmarking for food.
“It’s too easy for companies at the moment to game their credentials on food labels, particularly regarding environmental impact. We see it almost every day.
“We need a framework agreeing which impacts will be accounted for, and then we need to provide guidance to monitor those impacts.”
OmniAction co-founder and executive director Lise Colyer also leads editorial at Quota.Media . She adds, “One third of all greenhouse gas emissions are from agrifood; experts describe the supply chain as plagued by child and forced labour ; and poor and inadequate food is the biggest killer in the world. There’s an urgency to this.
“Every CEO is experiencing direct or indirect pressure around sustainability and ESG reporting.”
United Nations scientific experts have said the true impacts of the food system, including poor labour rights and environmental practices, cost society twice the value of the sector - US$19.8 trillion. This was emphasised in the True Value of Food report published by the Food Reform for Sustainability & Health project of the World Business Council for Sustainable Development.
OmniAction will curate ongoing data improvements, iterating toward a full framework addressing environmental impact, labour rights, land sovereignty, food safety and nutrition.
This will foster a consumer environment which progresses health and sustainability. And this in turn will foster changes in the industry and policy environments.
The launch team invites those keen to participate to register their interest and to join the official launch event.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005650/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
